Document Detail


New anticoagulants for atrial fibrillation.
MedLine Citation:
PMID:  19739042     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Atrial fibrillation is already the most common clinically significant cardiac arrhythmia and a common cause of stroke. Vitamin K antagonists are very effective for the prevention of cardioembolic stroke but have numerous limitations that limit their uptake in eligible patients with AF and reduce their effectiveness in treated patients. Multiple new anticoagulants are under development as potential replacements for vitamin K antagonists. Most are small synthetic molecules that target factor IIa (e.g., dabigatran etexilate, AZD-0837) or factor Xa (e.g., rivaroxaban, apixaban, betrixaban, DU176b, idrabiotaparinux). These drugs have predictable pharmacokinetics that allow fixed dosing without laboratory monitoring, and are being compared with vitamin K antagonists or aspirin in phase III clinical trials [corrected]. A new vitamin K antagonist (ATI-5923) with improved pharmacological properties compared with warfarin is also being evaluated in a phase III trial. None of the new agents have as yet been approved for clinical use.
Authors:
Magdalena Sobieraj-Teague; Martin O'Donnell; John Eikelboom
Publication Detail:
Type:  Journal Article; Review     Date:  2009-09-08
Journal Detail:
Title:  Seminars in thrombosis and hemostasis     Volume:  35     ISSN:  1098-9064     ISO Abbreviation:  Semin. Thromb. Hemost.     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-09-09     Completed Date:  2009-12-31     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  0431155     Medline TA:  Semin Thromb Hemost     Country:  United States    
Other Details:
Languages:  eng     Pagination:  515-24     Citation Subset:  IM    
Copyright Information:
Copyright Thieme Medical Publishers.
Affiliation:
McMaster University, Hamilton, Ontario, Canada. teaguem@mcmaster.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticoagulants / therapeutic use*
Atrial Fibrillation / drug therapy*
Benzamides / therapeutic use
Benzimidazoles / therapeutic use
Biotin / analogs & derivatives,  therapeutic use
Clinical Trials, Phase III as Topic
Factor Xa / antagonists & inhibitors
Humans
Morpholines / therapeutic use
Oligosaccharides / therapeutic use
Pyrazoles / therapeutic use
Pyridines / therapeutic use
Pyridones / therapeutic use
Thiazoles / therapeutic use
Thiophenes / therapeutic use
Vitamin K / antagonists & inhibitors
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Benzamides; 0/Benzimidazoles; 0/Morpholines; 0/Oligosaccharides; 0/Pyrazoles; 0/Pyridines; 0/Pyridones; 0/Thiazoles; 0/Thiophenes; 0/idrabiotaparinux; 0/idraparinux; 0/rivaroxaban; 12001-79-5/Vitamin K; 2E18WX195X/dabigatran etexilate; 3Z9Y7UWC1J/apixaban; 480449-70-5/edoxaban; 58-85-5/Biotin; 74RWP7W0J9/betrixaban; EC 3.4.21.6/Factor Xa
Comments/Corrections
Erratum In:
Semin Thromb Hemost. 2009 Oct;35(7):711

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Patent foramen ovale and cryptogenic stroke: a matter of age?
Next Document:  No Article Title